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Klebsiella infections, including catheter associated urinary tract infections, are a considerable burden on health
care systems. This is due to their difficulty to treat, caused by antimicrobial resistance and their ability to form
biofilms. In this study, we investigated the use of a Klebsiella phage cocktail to reduce biofilm viability. We used
two methodologies to investigate this, a standard 96-well plate assay and a more complicated Foley catheter-
based model. The phage cocktail was used alone and in combination with clinically relevant antibiotic treat-
ments. Viability was measured by both a resazurin based stain and colony forming unit counts, of cells sloughed
off from the biofilm. We showed that phage infection dynamics and host survival vary significantly in different
standard laboratory media, presumably due to the expression of different surface receptors and capsule compo-
sition by the bacteria effecting phage binding. This underscores the importance of a realistic model for developing
phage therapy.
We demonstrate that bacteriophage-based treatments are a viable option for preventing Klebsiella colonisation
and biofilm formation on urinary catheters. Phage cocktails were able to significantly reduce the amount of
biofilm that formed when they were present during early biofilm formation. The phages used in this study were
unable to significantly reduce a pre-formed mature biofilm, despite encoding depolymerases. Phages applied
together with antimicrobial treatments, showed synergistic interactions, in some cases the combined treatment
was much more effective than antimicrobial treatments alone.
We show that phage cocktails have the potential to prevent Klebsiella biofilms in catheters, if used early or as a
preventative treatment and will work well alongside standard antibiotics in the treatment of catheter-associated
urinary tract infections (CAUTI).Introduction
Carbapenem-resistant and third-generation cephalosporin-resistant
Enterobacteriaceae, such as Klebsiella sp. have been named by the World
Health Organisation (WHO) as one of the critical priority bacteria in the
fight against antibiotic resistance [1]. Klebsiella species cause a variety of
opportunistic infections including urinary tract infection (UTI), pneu-
monia, septicaemia, wound infection, and infections in vulnerable pa-
tients including neonates and intensive care patients [2]. Klebsiella
species can encode virulence factors which make them efficient patho-
gens, but of most concern are the high levels of multiple antibiotic
resistance mechanisms found within the genus. Resistance rates within
pathogenic Klebsiella sp. have increased exponentially to most available
antimicrobial drugs, with multidrug resistance seen in UTI associated
Klebsiella [3,4] and cases of pan-resistant Klebsiella described [5,6].k (E. Jameson).
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evier B.V. This is an open accessAntibiotic resistance within the Klebsiella genus is mediated by antibiotic
resistance genes encoded for in both their chromosome and mobile
plasmids [7–9]. This increased resistance is often associated with an
increased risk of mortality [10].
Complicating the antibiotic resistance of Klebsiella species is their
ability to form biofilms. It has been shown with some antibiotics, that
lack of penetration into the biofilm prevents killing of Klebsiella, however
there are other mechanisms at work [11]. The thickness of mature
Klebsiella biofilm has been implicated in increased antibiotic tolerance as
well as biofilm heterogeneity [12]. Nutrient limitation, leading to lack of
growth, has also been shown to contribute to antibiotic tolerance even
with full penetration of the drug [12,13]. It has also been shown that
sub-lethal concentrations of antibiotics, often found within biofilms, can
increase the virulence, biofilm formation and antibiotic resistance of
Klebsiella species [14,15]. These biofilm properties confer the benefit ofOctober 2020
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Table 1
Description of Klebsiella clinical isolates used in this work. Klebsiella clinical
isolates used in this work are described within this table including their Genus,
species, strain identification (ID) number and source of isolation.
Species Strain ID Source
Klebsilla pneumoniae 170723 Urine
Klebsiella oxytoca 170748 Catheter Specimen Urine
Klebsiella pneumoniae 170958 Urine
Klebsiella oxytoca 171266 Urostomy urine
Table 2
Description of phage used in this work. Phage used in this work are described
within this table including their full name, isolation host and source of isolation.







vB_KppS-Strom Sewage - storm tank
storage
vB_KppS-Pokey Sewage - anoxic
sludge
vB_KppS-Anoxic Sewage - anoxic
sludge
vB_KoM_Flushed Klebsiella pneumoniae170958 Sewage - mixed liquor
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this phenotype, which differs from antibiotic resistance conferred by
antibiotic resistance genes. However, Klebsiella strains that possess the
ability to form rigid biofilms are also more likely to be
Extended-Spectrum Beta-lactamase (ESBL) producers [16], as well as
having increased ability to transfer plasmids within biofilm [15], which
further complicates therapy.
The ability to form biofilms means Klebsiella spp. are able to colonise
medical devices, leading to central line associated sepsis, ventilator
associated pneumonia, and catheter associated urinary tract infections.
Klebsiella penumoniae and Klebsiella oxytoca have both been found to be
common causes of Catheter Associated Urinary Tract Infections (CAUTI)
with high rates of antimicrobial resistance [17–19].
Bacteriophages offer an alternative method of treating biofilm in-
fections. The lytic lifecycle of phages is a virulent lifestyle that results in
bacterial death, this lifestyle can be taken advantage of for therapeutic
use. Lytic phages are preferential for therapeutic use, because temperate
phages may increase the fitness of their hosts, as well as the potential
presence of antimicrobial resistance and toxin genes in temperate phages
[20]. Utilising lytic phages as antibacterial agents was first described by
d’Herelle in 1919, and he summarised his successes in a review in 1931
[21]). Phages offer a number of advantages over antibiotics as
anti-biofilm agents, including increased specificity, accuracy and potency
[22,23]. Phages are able to degrade the biofilm extracellular matrix,
allowing antimicrobial penetration, lysis of bacterial cells and extensive
biofilm disruption [24,25].
Phage coating for catheters have already been developed for other
common CAUTI pathogens such as Proteus mirabilis, Escherichia coli,
Pseudomonas aeruginosa [26,27], and combinations of these bacteria in
polymicrobial biofilms [28,29]. Small scale clinical trials have been
conducted, which show the efficacy of phages on catheters in vivo [30].
However, to our knowledge, there currently exists no equivalent treat-
ment for Klebsiella caused CAUTI.
CAUTI associated Klebsiella present a novel bacteriophage target and
unique challenges [31]. demonstrated that their UTI Klebsiella isolates
showed a mucoid phenotype and that higher drug-resistant corelated to
biofilm formation and polysaccharide production in Klebsiella. Poly-
saccharide production is widespread in Klebsiella sp., with 77 different
capsule types having previously been serologically defined [32,33].
These protective polysaccharide capsules endow resistance to not only
antibiotics, but also protists and phages [34,65]. In response phage tail
fibres are highly diverse and frequently rearranged, often consisting of
enzymes that can degrade bacterial structures, such as depolymerases
that target bacterial capsules [35]. These enzymes may facilitate diffu-
sion of phage, or antimicrobial drugs, into the biofilm, which is a
commonly cited cause for antimicrobial tolerance in biofilms [12].
In this paper, we investigate the potential for a number of previously
described Klebsiella phages [36] to be used as anti-biofilm agents in
preventing CAUTI. Using a number of urinary-isolated Klebsiella species
we developed an in vitro model of CAUTI biofilms, which we used to test
combinations of antimicrobial drugs alongside a phage cocktail. Our in
vitromodel was based around the use of artificial urine media (AUM) and
sections of Foley catheter. We showed that the phage cocktail and anti-
microbial therapy are in some cases able to complement each other’s
activity, leading to an enhanced anti-biofilm effect.
Materials and methods
Culture conditions and standardisation
Strains used in this study were from culture collections or clinical
strains. The clinical strains (Klebsiella pneumoniae 170723, Klebsiella
oxytoca 170748, Klebsiella pneumoniae 170958, and Klebsiella oxytoca
171266) were all isolated in the UK from urinary tract infections, with or
without the presence of a medical device, described in Table 1. Type
strain Klebsiella pneumoniae subsp. pneumoniae 30104 was obtained from2
the DSMZ culture collection (Leibniz Institute, Germany). All isolates
were stored long-term at 80 C and short-term at 4 C. Strains were
maintained on LB agar and propagated in Cation-adjusted Mueller Hin-
ton Broth (CAMHB, Sigma-Aldrich, Gillingham, UK). After growing to
exponential phase (OD600nm 0.4–0.6), cells were washed with phosphate
buffered saline (PBS, Oxoid, Basingstoke, UK; 0.137 M NaCl2, 3 mM KCl,
8 mM Na2HPO4, 1.5 mM KH2PO, pH 7.3) and normalised based on op-
tical density at 600 nm before experimental work.
Bacterial growth media
The bacterial growth media used within this study is specified for
each technique, includes Cation-adjustedMueller Hinton Broth (CAMHB,
Sigma-Aldrich, Gillingham, UK), Luria Broth (LB, Sigma-Aldrich, Gil-
lingham, UK), M9minimal media [37] supplemented with 5 mM glycerol
and Artificial Urine Medium (AUM) [38].
Bacteriophages
Bacteriophages used in this paper were isolated and characterised by
our lab group; the bacteriophages are genetically distinct, span four
different phage genera and demonstrated different host ranges described
in Ref. [36]. The phage used in this study, their isolation host strain, and
source have been described in Table 2. Single phages were used for
treatment, as well as a cocktail consisting of all six phages, in equal
portions, as determined by plaque forming units (PFU ml1). Phages are
used as a cocktail for therapeutic use, with the aim of overlapping host
range and activity to overcome any specificity the individual phage may
have. Strain susceptibility to each phage is described in Table S1.
Biofilm formation in cell-culture plates
All Klebsiella strains were standardised to 1 102 CFU/mL in CAMHB.
CAMHB was selected because it is the industry standard method to
measure the efficacy of antimicrobials using the minimum inhibitory
concentration (MIC) method. Into a 96-well flat bottom cell culture
treated plate (CytoOne Plate, Starlab, UK), 200 μL of cell suspension was
added. Culture plate biofilms were used as a simple, in vitro biofilmmodel
to quickly determine the ability of Klebsiella strains to form biofilms and
bacteriophages ability to inhibit biofilm formation and biofilms. To form
a biofilm, the plates were incubated statically for 16 h at 37 C. After 16
E.M. Townsend et al. Biofilm 2 (2020) 100038h, biofilm viability had stabilised and therefore were now considered
mature (Fig. S1). All procedures were carried out in a Class II microbi-
ological safety cabinet. Negative controls containing no inoculum, and
positive controls which had no treatment applied, were included in each
plate. All testing was carried out in triplicate, on three separate occasions.
Phage and Antimicrobial Treatment in cell-culture plates.
For investigating phage inhibition of biofilm formation, 10 μL of
phage suspension was added to the well before any bacteria were added.
Biofilms were then allowed to form, as described above.
To treat mature biofilms, the biofilms were first washed with PBS to
remove any planktonic cells. Following this, 10 μL of phage stock sus-
pension (1  102 PFU/mL) was added to each well. Meropenem was
selected for treatment because the Klebsiella strains used showed varying
degrees of susceptibility based on the MIC’s calculated for each strain
(Table S2). All strains had reduced susceptibility in the biofilm pheno-
type. For treatment with meropenem for 5 h, the drug was suspended in
CAMHB at 128 mg/L and 64 mg/L for high and low concentrations
respectively. Untreated controls and negative controls were included in
every experiment. The experiments were performed in triplicate.
Phage infection in different media
Klebsiella strains were grown to exponential phase in four different
media (LB, CAMHB, M9 supplemented with 5 mM glycerol and AUM
[38]). The strains were then diluted to an OD600nm which was equivalent
to approximately 1  107 CFU/mL and 150 μL of bacterial suspension
was added per well in a 96-well microtitre plate. The wells then had
either 50 μL phage cocktail (test wells) or 50 μL media (control wells)
added.
The 96-well microtitre plate was sealed and incubated at 37 C with
shaking at 200 rpm in between readings and 500 rpm for 30 s before
readings in a FLUOstar® Omega plate reader (BMG Labtech, Aylesbury,
UK). The optical density of the cultures was recorded over 24 h, with
readings at OD600nm taken every 5 min. Each plate contained technical
duplicates for each Klebsiella strain in each media and was performed in
biological triplicate.
The area under the curve (AUC) was calculated using MatLab,
following the methodology of [39]. The AUC method allowed direct
comparison of the phages in each host and media in a high-throughput
and reproducible manner. The ratio of bacteria-only control AUC to
phage infected AUC was calculated for each growth media. For each
strain, the AUC ratio was normalised by Ln transformation and then each
media was compared using a two-tailed t-test to identify where phage
infection was affected by the growth media.
Biofilm formation and treatment in simple catheter model.
Foley catheters (Folatex ref. AA1B16 Ch/Fr 16/5.33, 30–45 mL/cc,
silicone coated latex urinary catheter/straight/2-way) were cut into 1.5
cm long sections, aseptically. A bacterial suspension of 1  102 CFU/mL
in CAMHB was formed by diluting from an exponentially growing cul-
ture. The catheter sections were incubated in the bacterial suspension for
2 h, at 37 C at 150 rpm. Following incubation, foley catheters sections
were transferred to a 24-well cell-culture plate (CytoOne Plate, Starlab,
UK) containing 1.5 mL AUM [38]. Phage cocktail (1  102 PFU/mL) was
added at the initiation of biofilm formation, where it was diluted 1 in 7 in
1.5 mL AUM. Biofilms with and without phage cocktail were incubated
statically for 16 h at 37 C. After 16 h the biofilms were considered
mature, as increases in viability had plateaued (Fig. S1). Before antimi-
crobial treatment, catheter sections were rinsed in PBS to remove any
planktonic or loosely adhered cells. Meropenem, mecillinam, or
trimethoprim were then added at 164 mg/L or 64 mg/L in AUM to the
biofilm. As trimethoprimwas dissolved in Dimethyl sulfoxide (DMSO), as
an additional control, DMSO was added to AUM without trimethoprim.
Meropenem and mecillinam stocks were dissolved in water. After the
addition of drug, biofilms were further incubated for 5 h before being
removed for analysis, to allow the drugs to penetrate into the biofilm,
mirroring the previous microtitre plate experiments. Untreated controls3
and negative controls were included in every experiment. The experi-
ments were performed in triplicate.
Biofilm viability analysis
Media and treatments were removed from the biofilm by pipetting off
overlying media followed by rinsing in PBS, and viability was assessed
using 10 μg/mL resazurin sodium salt. Briefly, resazurin salt was diluted in
CAMHB from a x100 stock solution. This was then applied to the biofilms,
200 μL for cell-culture plate biofilms or 1.5 mL for Foley catheter biofilms,
and incubated for approximately 2 h at 37 C. Absorbancewasmeasured at
OD 570 nm and 600nm and used to calculate the percentage viability, relative
to negative controls incubated in each plate [40].
For the Foley Catheter biofilms, the viability was also analysed by
incubating the treated section of catheter in 2 mL CAMHB for 2 h at 37 C
at 150 rpm. This regrowth bacterial suspension was then used for Miles
and Misra counts to assess the CFU/mL. Briefly, the bacterial suspension
was serially diluted 1 in 10 and then 10 μL plated out on LB agar plates in
triplicate. The plates were then incubated overnight at 37 C, the colonies
were counted and used to calculate the bacterial concentration in original
suspension.
Statistical analysis
Graphs were produced in MatLab (MatLab R2020a) and GraphPad
Prism (Prism version 8.2.4). Unpaired two-tailed t-tests were used to
establish significant differences between treated samples and untreated
controls. Percentage viability scores were log2 transformed before sta-
tistical analysis took place. A 2-way ANOVA with Sidak’s multiple
comparison test was used to establish any differences between phage
infection in different bacterial growth media. Statistical significance was
achieved if p < 0.05.
Results
Single phage treatment is able to prevent biofilm formation, but the
phage cocktail has a wider range of activity.
Phage had been added to the biofilm grown in CAMHB in 96-well
microtitre plates, both at the initiation of biofilm formation (Fig. 1A),
and after biofilms had matured (16h, Fig. S1), for a treatment period of 5
h (Fig. 1B). This treatment period had been selected in optimisation
stages (Fig. S2).
Single phage treatments were able to prevent biofilm formation in a
number of strains (Fig. 1A), although strains varied in susceptibility to
individual phage. Phage KoM-Flushed had the widest host range, being
able to significantly reduce biofilm formation in four out of five strains
(170748, 170958, 171266, and 30104), this correlated to a decrease in
viability from 60 to 80% with no treatment down to 15–20% biofilm
viability with phage treatment, a 40–60% drop. Phage KppS-Anoxic was
able to significantly reduce biofilm viability in three strains (170748,
170723, 171266) equal to 20–50% drops, while KppS-Samwise and
KppS-Jiji both caused significant reductions in 171266 and 170748,
equal to 25–50% drops. Phage KppS-Pokey was only able to significantly
reduce biofilm formation by 15% in 171266. Finally, KppS-Storm was
unable to cause any significant reductions in biofilm formation in any
strains. When these phages were combined to create a phage cocktail,
this treatment significantly reduced biofilm formation in all strains
except 170723.
When added onto a mature biofilm (Fig. 1B) there were no significant
reductions in the viability of the biofilm, with the exception of KppS-
Anoxic in strain 30104. Therefore, at this point the results already
showed that phage treatment is more effective at preventing biofilm
formation rather than penetrating and killing a mature biofilm commu-
nity. Higher phage PFUs were not tested, but may improve the efficacy of
phage treatment against mature biofilms, however we concentrated our
efforts on the promising prevention strategy.
Fig. 1. Individual phage and phage cocktail are able
to reduce the viability of some, but not all, Klebsiella
biofilms. Phage were added to biofilms either indi-
vidually or combined in a cocktail (PhC) at the start
(A) of biofilm formation, as a preventative, or for 5 h
(B) to a mature Klebsiella biofilms, as described in the
methods. Biofilms were analysed using the resazurin
viability stain. Some individual phage were able to
reduce biofilm viability when added at the start of
biofilm formation (A), and in four strains the cocktail
was effective when added at this point. When used
on a mature biofilm (B), there was very limited ef-
fects on biofilm viability. Symbols denote significant
difference (t-test); * compared to positive control, *
denotes p value  0.05, **, p  0.01, ***, p  0.001.
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E.M. Townsend et al. Biofilm 2 (2020) 100038Combination of the phage cocktail and meropenem is more effective
than monotreatments.
Biofilms were again grown in CAMHB in 96-well microtitre plates and
challenged with two different doses of meropenem, the phage cocktail,
and a combination of meropenem and phage cocktails (Fig. 2). Mer-
openem concentrations were selected based on average MIC data
(Table S2), strains had an increased MIC in biofilm assays compared to
planktonic. The phage cocktail was again added at the start of biofilm
formation (Fig. 2A) or onto a mature biofilm (Fig. 2B), while meropenem
treatments were added after the biofilm had matured. This was intended
to replicate two clinical senarios; a phage coated product where phage
prevent biofilm formation, and a traditional phage infusion where phage
interact with a preformed biofilm. As antibiotics would only be given
upon clinical signs of infection, therefore would only be applied to a
mature biofilm, these were added after 16 h. To assess the combined
treatment effects we use the terms defined by Ref. [41]: synergy, facili-
tation and antagonism. The term synergy denotes a reduction in Klebsiella
biofilm by the combined treatments that is greater than anticipated based
on the sum of the individual treatments. Facilitation describes a reduc-
tion in biofilm by the combined treatment that surpasses either indi-
vidual treatment, but is less than the combined sum of the treatments.
Antagonism refers to when the combined treatment effect is worse than
the individual treatments. The lytic spectra of the phage is listed in
Table S1., but this does not appear to correlate to the antibiofilm activity
of the phage cocktail.
As in previous tests, 170723 was unaffected by the phage cocktail, as
well as the meropenem treatment at both time points. In fact, we saw
antagonism, with a small, yet significant increase in viability when the
biofilm was exposed to high levels of meropenem.
When the phage cocktail was added at the start we saw synergy be-
tween meropenem and the phage cocktail for the other four strains
(170748, 170958, 171266, and 30104). These were not seen in the
mature biofilm. No significant reduction compared to the control was
seen for 170958 in the mature biofilm. Strains 170748 and 171266
showed individual treatment effects in the mature biofilm, but no addi-
tional combined, while strain 30104 showed synergy between the
highest level of meropenem and the phage cocktail in the mature biofilm.
The type strain 30104 does not form as robust a biofilm in comparison
to the other strains (Fig. S3), as demonstrated by the comparatively lower
percentage viability in the positive control compared to the other Kleb-
siella strains. However, the phage cocktail alone was still able to cause a
significant reduction. On the mature biofilm, these effects were less
evident, and the phage cocktail was not effective.
Phage infection varies dependent on growth media
Having demonstrated the impact of the phages on biofilm formation
in the standard CAMHB-well plate model, we moved forwards with the
development of a more reflective in vitro model of CAUTI, by investi-
gating phage infection in a series of rich and more minimal growth
media. We continued with our use of CAMHB, and additionally tested in
LB, M9 supplemented with glycerol as a carbon source, and AUM. We
suspected that CAMHB as a rich media would not provide realistic re-
sults, but had concerns if phage infection would still occur in more
minimal and restrictive growth media.
The phage cocktail was used to infect each bacterial strain plank-
tonically in four different growth media, LB, CAMHB, M9 supplemented
with 5 mM glycerol, and AUM (Fig. 3A). As rates of bacterial growth also
differ in each media, the ratio of area under the curve (AUC) in a bacteria
only control and bacteria infected with phage was calculated in each
media (Fig. 3B).
An ANOVA with Sidak’s multiple comparison tests was used to
analyse the data. The data was analysed for interaction effects, and in all
but 170958, the two factors (phage and media) did not interact. There-
fore, in the four remaining strains, the effects of phage and media were
independent of each other.5
The media accounted for variance in strains 170723 (p value ¼
0.0185, 32.95%), 170748 (p value < 0.0001, 83.51% variance) and was
near significant for 170958 (p value ¼ 0.0542, 17.23% variance). The
presence or absence of phage accounted for variance in the type strain
30104 (p value¼ 0.0021, 37.12%), 170723 (p value¼ 0.0390, 12.44%),
170748 (p value ¼ 0.0008, 7.145%) and 170958 (p value ¼ 0.0006,
33.5% variance). The results in 170958 were difficult to interpret as
there was interaction between the two factors (p value¼ 0.0349, 20.07%
variance).
For 30104 there were no significant differences betweenphage in
each media, but it can be seen that there was a more marked decrease in
AUC in the LB andMHmedia. Similarly but in different media for 170723
there was an observable reduction of the AUC in MH and M9/Gly. For
170748 there were modest decreases in AUC with phage in media LB and
MH, but only the decrease in AUM media was significant (0.0059). In
strain 171266, neither the effects of media or phage were considered
significant. However, in each media there is a slight decrease in the mean
AUC in the presence of phage. There was also a significant decrease in
170958 AUC with phage in both M9/Gly (0.0019) and AUM (0.0262).
Overall, these results show that the nutritional environment that the
host bacteria are growing in can influence the cell lysis by phage,
although this varies dependent on the host strain. Therefore, we decided
to continue our experiments using AUM for a growth media, as this both
allowed phage infection to occur in a number of strains planktonically, as
well as being close to the clinical situation we are attempting to mimic.
Biofilms in the in vitro foley catheter model
The meropenem treatment in combination with the phage cocktail
significantly reduced the viability of the biofilm in three clinical strains;
170723, 170958, and 170748 (Fig. 4A). For 170723, the combined effect
was synergistic, while facilitation was observed in strains 170958, and
170748. For strains 171266 and 30104, the reductions in biofilm
viability in response to all treatments were not significant (Fig. 4A).
The second analysis for meropenem was of colony forming units
counts of bacterial cells sloughed off from the biofilm (Fig. 4B). This is
linked to what is within the biofilm itself, as well as giving an indication
to likelihood of infection to disperse from the biofilm and disseminate
after treatment. However, it is unclear if these sloughed off cells should
be considered as planktonic cells or a small piece of biofilm, this is an
important consideration because phages infect planktonic cells differ-
ently to intact biofilms. Correspondingly the results are less clear, with
only 170723, 170748, and 171266 showing significant reductions in
colony counts after either meropenem or combination treatments. Posi-
tive controls contained 3.73  108, 1.79  108, 1.63  108, and 3.86 
108, 4.38  107 CFU/mL for 170723, 170958 170748, 171266, and
30104 respectively. Combination treatments caused an average 2.69 log
reduction (range 1.81–4.16 logs) while phage alone caused a 0.05 in-
crease (range 0.36-0.28) and drug alone caused a 1.59 log reduction
(high 1.74, 1.14–2.88, low, 1.45, 0.65–2.01). Only 170723 treated with
low level meropenem and the phage cocktail (1.37  106 CFU/mL)
showed a significant reduction in colony forming units counts compared
to low level meropenem treatment alone (8.11  106 CFU/mL).
The next drug used was mecillinam, a second-line antibiotic used for
CAUTI [42]. Klebsiella should be intrinsically resistant to this penicillin
antibiotic, therefore it is not surprising that the phage treatment was
driving the reduction in viability of the biofilm here (Fig. 5A). Phage
treatment repeatedly resulted in the lowest Klebsiella viability significantly
lower than the control for 170958, 171266 and 30104, but were not
significantly different from the combined mecillinam and phage treat-
ment. In strains 170723, 170958, and 171266, the combined mecillinam
and phage treatment resulted in were significantly lower biofilm viability
compared to the mecillinam alone. The colony forming unit analysis
showed no significant differences regardless of treatment (Fig. 5B).
Trimethoprim was the final drug used, a first-line antibiotics in the
treatment of CAUTI [42]. As the drug needed to be suspended in DMSO,
Fig. 2. There is synergy between phage cocktail and
meropenem when used to prevent biofilm formation.
Phage treatments when added at the start (A), as a
biofilm prevention strategy, or for 5 h (B) to the
mature Klebsiella biofilms as described in the
methods. Biofilms were analysed using the resazurin
viability stain. Klebsiella strain 170723 had no sig-
nificant reductions in biofilm viability, however all
other strains showed some reductions, and there
appeared to be a synergistic effect when used in
combination with meropenem. Symbols denote sig-
nificant difference (t-test); * compared to positive
control, # compared to corresponding phage cocktail
treatment, and ~ compared to corresponding mer-
openem treatment. */#/~ denotes p value  0.05,
**/##/~~, p  0.01, ***/###/~~~, p  0.001.
E.M. Townsend et al. Biofilm 2 (2020) 100038
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Fig. 3. Infection curves and area under the curve analysis for five Klebsiella strains infected with the same phage cocktail in four different media. Infection of five
Klebsiella strains was performed as described in the methods and monitored spectrophotometrically over 24 h (A). Bacteria only controls were performed alongside
bacteria infected with phage cocktail. Line displays the mean optical density, error bars display standard error across biological triplicates. Area under the curve
analysis was performed on the curves (B) to analyse differences in growth rate between media and in presence/absence of phage cocktail. * Denotes significant
difference (p < 0.05) between bacterial growth with and without phage cocktail, * denotes p value  0.05, **, p  0.01, ***, p  0.001.
E.M. Townsend et al. Biofilm 2 (2020) 100038all other treatments and the positive control also had DMSO added to
control for any additional effects.
In strain 170958 and 30104, all treatments significantly decreased
the percentage viability of the biofilms. In 170748, high trimethoprim7
with the phage cocktail, low trimethoprim, and low trimethoprim with
phage significantly reduced the viability of the biofilm (Fig. 6A). In strain
171266, all treatments except low trimethoprim were able to signifi-
cantly reduce the viability of the biofilm. In strain 170723, despite
Fig. 4. In a more complex model (Foley catheter in vitro model) treatments are less effective but are still able to cause some reduction in biofilm viability and
sloughing. Phage treatment was combined with meropenem in a Foley catheter in vitro model. Biofilm reduction was measured by viability assay (A) and CFU counts
(B). Treatments were able to reduce viability and sloughing, most notably in strain 170723 which had previously not responded to the same treatment in previous
testing. Symbols denote significant difference (t-test); * compared to positive control, # compared to corresponding phage cocktail treatment, and ~ compared to
corresponding meropenem treatment. */#/~ denotes p value  0.05, **/##/~~, p  0.01, ***/###/~~~, p  0.001.
E.M. Townsend et al. Biofilm 2 (2020) 100038
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Fig. 5. Mecillinam was not effective at reducing Klebsiella biofilms by either measure, and phage cocktail was more effective alone. Phage treatments were combined
with mecillinam, a second line drug used for treatment of CAUTI in the in vitro Foley catheter model. The treatment effect was measured by viability assay (A) and CFU
counts (B) as described in the methods. The viability staining showed that phage cocktail alone was more effective compared to drug alone or in combination. All
effects were lost when measured by CFU counts. Symbols denote significant difference (t-test); * compared to positive control, # compared to corresponding phage
cocktail treatment, and ~ compared to corresponding mecillinam treatment. */#/~ denotes p value  0.05, **/##/~~, p  0.01, ***/###/~~~, p  0.001.
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Fig. 6. Trimethoprim is effective at reducing Klebsiella biofilms and CFU counts show facilitation with phage cocktail. Phage treatments combined with trimethoprim,
a first line drug for CAUTI, measured by viability assay (A) and CFU counts (B) in an in vitro Foley catheter model. In the viability assay, all treatments were
approaching the lower limit of detection by the assay, therefore it is difficult to see any facilitation or synergy with the phage treatment. However, this is more evident
in the CFU counts where reductions are greater in the combination treatments. Symbols denote significant difference (t-test); * compared to positive control, #
compared to corresponding phage cocktail treatment, and ~ compared to corresponding trimethoprim treatment. */#/~ denotes p value  0.05, **/##/~~, p 
0.01, ***/###/~~~, p  0.001.
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E.M. Townsend et al. Biofilm 2 (2020) 100038reductions in viability, none of the changes caused by the treatments
were statistically significant. However, when analysed by CFU counts,
this change became significant (Fig. 6B), with 2.10 and 2.57 log re-
ductions in the high and low trimethoprim, and 3.31 and 4.01 log re-
ductions when they were combined with PhC. Strain 170748 also had
significantly lower CFU counts with every treatment, with the addition of
high trimethoprim and the phage cocktail (1.70  104 CFU/mL) being a
more significant reduction compared to trimethoprim alone (1.42  106
CFU/mL). In strains 171266 and 30104, the combined treatments
significantly reduced the CFU counts (171266, 4.21 and 4.24 log re-
ductions for high and low trimethoprim with PhC, 30104, 4.54 and 3.18
log reductions) compared to the phage treatment alone (171266, 2.18 log
reduction, 30104, 2.42, log reduction). Strain 170958 had no significant
changes to the CFU counts.
Discussion
In this paper we have shown that antibiotics can be used in combi-
nation with preventative phage cocktail treatments, synergistically to
reduce the amount of biofilm formation on urinary tract catheters. This
shows the potential of using phages to prevent Klebsiella CAUTI and the
further complications associated with Klebsiella infections.
We have also shown that using appropriate models is important,
particularly in respect to mimicking in vivo conditions. This has been
shown to be important for antibiotic treatments, but even more so for
phage infection, evidenced by the initial experiments comparing media
for planktonic phage infection and the varying response of strain 170723
in the two main biofilm models. The changes in phage efficacy may be
linked to corresponding changes in the availability of phage binding sites
such as the capsules of Klebsiella, it has previously been demonstrated
that encapsulation can be inhibited by carbohydrate restriction and the
ionic strength of growth media [43,44]. Although the model presented
here remains relatively simple, we have already shown that increasing
complexity is important in testing new treatments. We theorise that on
exposure to different media and surfaces, Klebsiella may vary their
capsule composition and cell surface receptors in the different environ-
ments and nutrient availability [45–48].
Mixtures of phages, commonly known as phage cocktails, are used for
therapeutic reasons over a lone phage for the same reason that drug
cocktails are often used in particularly recalcitrant infections such as HIV
or TB. Phage cocktails have a broader host range than individual phages,
reducing the chance of phage resistance emerging, which can maximise
the efficiency of therapy [49]. Phage resistance is a common phenomenon
in the natural predator-prey relationship between phages and bacteria.
More specifically in the case of Klebsiella biofilms, phages may possess
depolymerase enzymes [50,51] that are able to degrade either the bacte-
rial capsule or the extracellular matrix that protects cells within the bio-
film. Depolymerase action can then facilitate the penetration of
antimicrobial drugs into the biofilm or may uncover receptors for a sec-
ondary phage infection [52]. In this way, phage cocktails are protected
from resistance developing and the likelihood of synergistic interactions
increases. A phage cocktail was composed of six phages that had been
previously characterised by our group [36]. The phages selected repre-
sented the broadest host range phages and most genetically diverse of the
characterised phages in the laboratory at the time the experiments were
conducted. In this study, we shown that in a number of cases, phages
combined with an antimicrobial drug were able to cause a significant
reduction in biofilm viability compared to each treatment alone displaying
either synergy or facilitation. Our results indicate that the treatments have
a synergistic action when used together, but the precise mechanism behind
is yet to be elucidated. To further characterise this synergistic effect, in-
vestigations into the pharmacokinetics of the treatments would need to be
established to improve the quantification and nature of the observed ef-
fects of combining phage and antimicrobials.
Our study focusses on the use of meropenem, a carbapenem anti-
biotic, selected based on MIC data. In addition, we have used11trimethoprim, a sulphonamide, and mecillinam, a penicillin, which are
both recommended in the NICE guidelines for use in treatment of CAUTI
[42]. Trimethoprim was particularly effective against the Klebsiella
strains used in this study. So much so, that in the viability assay the re-
sults were approaching the lower limit of detection of the assay, making
it difficult to detect any additional benefit of co-treatment with phage.
However, these effects were better seen in the colony forming units
counts of cells sloughed off the biofilm, highlighting the benefits of using
multiple methods to measure treatment effects. Conversely, mecillinam
was not at all effective against the strains. This is not surprisingly as
Klebsiella have long been recognised as intrinsically resistant to penicillin
antibiotics [53]. The hypothesis behind choosing mecillinam was that
there may be some synergistic activity between the phage and drug
which would overcome this resistance. This has been previously
demonstrated where a phage’s depolymerase enzymes are able to
degrade the matrix and capsule of a bacteria, allowing antibiotic pene-
tration where it would not normally occur [54,55]. Unfortunately, this
was not the case here, despite the fact that phage KppS-Pokey has been
predicted to encode a depolymerase [36]. It is well characterised that
sub-inhibitory concentrations of antibiotics can stimulate biofilm for-
mation [56]. Instead this appears to be the effect seen here, where the
phage cocktail is the driving force in the reduction of viability and the
presence of mecillinam only stimulates the biofilm [14,15]. While the use
of a phage cocktail can theoretically assist drug penetration and increase
efficacy, it cannot substitute selection of an appropriate antibiotic.
In the development of our in vitro CAUTI model, we investigated
phage infection in different nutritional environments. The effects of
nutritional environment were briefly investigated by Storms et al. in the
development of the virulence index, a method of quantifying phage
virulence relative to the natural host growth rate [39]. In the study of
[39] it was also shown that temperature had an effect on phage virulence
alongside growth media, as well as the same phage having different
dynamics in secondary host strains. These are all factors that need to be
taken into consideration when optimising phage cocktails for use outside
of the lab. In this work, all experiments were carried out at 37 C to
mimic the temperature experienced in human infections.
There have been a number of studies for other urinary tract patho-
gens, where phages have been shown to be successful prevention stra-
tegies [28,29,57,58], sometimes in combination with a benign biofilm
[26]. These results have been shown in clinical or urinary tract pathogens
(but not Klebsiella) without any negative side effects being found to be
associated with the phage treatment [30]. Although larger studies are
required before phage treatments can overtake antibiotics, the current
evidence shows phage treatments are accepted by patients and can show
efficacy [30,59,60]. A review of current phage therapeutics, including
urinary tract catheters can be found here [60]. We propose that similar
phage therapeutics for urinary tract catheters could be developed for
Klebsiella. Phages have already been shown to be a valid method of
eradicating Klebsiella biofilms, even in multi-resistant strains [61–63],
depolymerases isolated from phage have also shown to have efficacy
[64]. Our Klebsiellamodel shows that phage cocktails have promise in the
prevention of Klebsiella CAUTIs, which would prevent complications in
vulnerable patients and prolong the time urinary catheters can remain in
situ.
Conclusions
This is the first time our in vitro CAUTI model has been presented, and
the first time the efficacy of antibiotics in combination with phage
cocktail has been tested on Klebsiella CAUTI biofilms. Our model provides
a simple, cheap in vitro model that is more realistic and reflective for
determining phage efficacy than 96 well plate models in standard rich
media. While it does lack certain properties, such as sheer stress from
urine passing over the biofilm, it provides the correct nutritional envi-
ronment and attachment surface for CAUTI biofilm growth. We believe it
provides a solid starting block to test promising phage, and other
E.M. Townsend et al. Biofilm 2 (2020) 100038antimicrobial, CAUTI therapies Phage cocktails shows synergy with the
current CAUTI antimicrobial treatments, trimethoprim and meropenem,
to help prevent biofilm formation by Klebsiella species in catheters. This
has important implications for clinical therapy, to offer an alternative
treatment for antimicrobial resistance Klebsiella.
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